BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8334428)

  • 1. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin.
    Rio B; Bauduer F; Arrago JP; Zittoun R
    Bone Marrow Transplant; 1993 Jun; 11(6):471-2. PubMed ID: 8334428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
    Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
    Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.
    Batsis I; Yannaki E; Kaloyannidis P; Sakellari I; Smias C; Georgoulis I; Fassas A; Anagnostopoulos A
    Thromb Res; 2006; 118(5):611-8. PubMed ID: 16330084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.
    Lee JH; Lee KH; Kim S; Lee JS; Kim WK; Park CJ; Chi HS; Kim SH
    Bone Marrow Transplant; 1998 Nov; 22(9):883-8. PubMed ID: 9827816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
    Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
    Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease.
    Salat C; Holler E; Göhring P; Poley S; Kolb HJ; Pihusch R; Reinhardt B; Krämling HJ; Haller M; Hiller E
    Eur J Med Res; 1996 Nov; 1(12):571-4. PubMed ID: 9438165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation].
    Inukai T; Sugita K; Goi K; Akahane K; Hirose K; Nemoto A; Takahashi K; Sato H; Uno K; Furuichi Y; Nakamura M; Miyamoto N; Yamakawa N; Shiraishi K; Kojika S; Tezuka T; Iijima K; Nakazawa S
    Rinsho Ketsueki; 2004 Apr; 45(4):297-303. PubMed ID: 15168445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Heikinheimo M; Halila R; Fasth A
    Blood; 1994 May; 83(10):3036-40. PubMed ID: 8180401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease.
    Bazarbachi A; Scrobohaci ML; Gisselbrecht C; Marolleau JP; Mansi A; Brice P; Gorra P; Drouet L
    Nouv Rev Fr Hematol (1978); 1993 Apr; 35(2):135-40. PubMed ID: 8332449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of procollagen-III peptide as a marker for veno-occlusive disease after bone marrow transplantation.
    Schuler U; Subat S; Schmidt H; Schneider A; Ehninger G
    Ann Hematol; 1996 Jul; 73(1):25-8. PubMed ID: 8695719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
    Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
    Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen.
    Eltumi M; Trivedi P; Hobbs JR; Portmann B; Cheeseman P; Downie C; Risteli J; Risteli L; Mowat AP
    Lancet; 1993 Aug; 342(8870):518-21. PubMed ID: 8102667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.